Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 9 Myelodysplastic Syndromes 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms 2 Multiple Myeloma 2 Lymphoma 2 Advanced Solid Neoplasm 2 Solid Tumors 1 Renal Insufficiency 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Liver Diseases 1 Leukemia, Prolymphocytic, B-Cell 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Central Nervous System Neoplasms 1 Advanced Solid Tumors 1 Advanced Nonhematologic Malignancies 1

Interventions

pembrolizumab 92 Nivolumab 56 Ipilimumab 55 Cyclophosphamide 52 Vemurafenib 28 fludarabine 27 aldesleukin 25 Interleukin-2 25 fludarabine phosphate 21 trametinib 20 dabrafenib 17 Temozolomide 14 Biopsy 14 Cisplatin 13 spartalizumab 12 atezolizumab 12 Carboplatin 11 cobimetinib 10 Paclitaxel 10 Introns 10 CTLA-4 Antigen 10 poly ICLC 9 binimetinib 9 Specimen Handling 9 Radiotherapy 9 Radiosurgery 9 MART-1 Antigen 9 tremelimumab 8 incomplete Freund's adjuvant 8 Radiation 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Melanoma × pevonedistat × Clear all

NCT01011530 2013-07-16

Dose Escalation Study of MLN4924 in Adults With Melanoma

Millennium Pharmaceuticals, Inc.

Phase 1 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡